One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry

B. Glintborg; I.J. Sørensen; E. Omerovic; F. Mehnert; N. Manilo; K. Danebod; D.V. Jensen; H. Nordin; A.G. Loft; O. Hendricks; S. Chrysidis; B.L. Andersen; J.L. Raun; H. Lindegaard; J. Espesen; S.H. Jakobsen; I.M.J. Hansen; E.B. Dalsgaard; D.D. Pedersen; S. Kristensen; A. Linauskas; L.S. Andersen; J. Grydehøj; N. Krogh; M.L. Hetland

doi:10.1136/annrheumdis-2018-eular.2113

One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry

B. Glintborg, I.J. Sørensen, E. Omerovic, F. Mehnert, N. Manilo, K. Danebod, D.V. Jensen, H. Nordin, A.G. Loft, O. Hendricks, S. Chrysidis, B.L. Andersen, J.L. Raun, H. Lindegaard, J. Espesen, S.H. Jakobsen, I.M.J. Hansen, E.B. Dalsgaard, D.D. Pedersen, S. KristensenA. Linauskas, L.S. Andersen, J. Grydehøj, N. Krogh, M.L. Hetland

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

10 Citationer (Scopus)

Originalsprog	Engelsk
Artikelnummer	THU0189
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	77
Udgave nummer	Suppl 2
Sider (fra-til)	313-314
ISSN	0003-4967
DOI	https://doi.org/10.1136/annrheumdis-2018-eular.2113
Status	Udgivet - 2018

Adgang til dokumentet

10.1136/annrheumdis-2018-eular.2113

http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-eular.2113

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Glintborg, B., Sørensen, I. J., Omerovic, E., Mehnert, F., Manilo, N., Danebod, K., Jensen, D. V., Nordin, H., Loft, A. G., Hendricks, O., Chrysidis, S., Andersen, B. L., Raun, J. L., Lindegaard, H., Espesen, J., Jakobsen, S. H., Hansen, I. M. J., Dalsgaard, E. B., Pedersen, D. D., ... Hetland, M. L. (2018). One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry. Annals of the Rheumatic Diseases, 77(Suppl 2), 313-314. Artikel THU0189. https://doi.org/10.1136/annrheumdis-2018-eular.2113

One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry. / Glintborg, B.; Sørensen, I.J.; Omerovic, E. et al.
I: Annals of the Rheumatic Diseases, Bind 77, Nr. Suppl 2, THU0189, 2018, s. 313-314.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Glintborg, B, Sørensen, IJ, Omerovic, E, Mehnert, F, Manilo, N, Danebod, K, Jensen, DV, Nordin, H, Loft, AG, Hendricks, O, Chrysidis, S, Andersen, BL, Raun, JL, Lindegaard, H, Espesen, J, Jakobsen, SH, Hansen, IMJ, Dalsgaard, EB, Pedersen, DD, Kristensen, S, Linauskas, A, Andersen, LS, Grydehøj, J, Krogh, N & Hetland, ML 2018, 'One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry', Annals of the Rheumatic Diseases, bind 77, nr. Suppl 2, THU0189, s. 313-314. https://doi.org/10.1136/annrheumdis-2018-eular.2113

Glintborg B, Sørensen IJ, Omerovic E, Mehnert F, Manilo N, Danebod K et al. One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry. Annals of the Rheumatic Diseases. 2018;77(Suppl 2):313-314. THU0189. doi: 10.1136/annrheumdis-2018-eular.2113

@article{bd9deee7a6544956a8716755377a2d37,

title = "One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry",

author = "B. Glintborg and I.J. S{\o}rensen and E. Omerovic and F. Mehnert and N. Manilo and K. Danebod and D.V. Jensen and H. Nordin and A.G. Loft and O. Hendricks and S. Chrysidis and B.L. Andersen and J.L. Raun and H. Lindegaard and J. Espesen and S.H. Jakobsen and I.M.J. Hansen and E.B. Dalsgaard and D.D. Pedersen and S. Kristensen and A. Linauskas and L.S. Andersen and J. Grydeh{\o}j and N. Krogh and M.L. Hetland",

year = "2018",

doi = "10.1136/annrheumdis-2018-eular.2113",

language = "English",

volume = "77",

pages = "313--314",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "Suppl 2",

}

TY - ABST

T1 - One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry

AU - Glintborg, B.

AU - Sørensen, I.J.

AU - Omerovic, E.

AU - Mehnert, F.

AU - Manilo, N.

AU - Danebod, K.

AU - Jensen, D.V.

AU - Nordin, H.

AU - Loft, A.G.

AU - Hendricks, O.

AU - Chrysidis, S.

AU - Andersen, B.L.

AU - Raun, J.L.

AU - Lindegaard, H.

AU - Espesen, J.

AU - Jakobsen, S.H.

AU - Hansen, I.M.J.

AU - Dalsgaard, E.B.

AU - Pedersen, D.D.

AU - Kristensen, S.

AU - Linauskas, A.

AU - Andersen, L.S.

AU - Grydehøj, J.

AU - Krogh, N.

AU - Hetland, M.L.

PY - 2018

Y1 - 2018

U2 - 10.1136/annrheumdis-2018-eular.2113

DO - 10.1136/annrheumdis-2018-eular.2113

M3 - Conference abstract in journal

SN - 0003-4967

VL - 77

SP - 313

EP - 314

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl 2

M1 - THU0189

ER -